- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04149158
Evaluation of Sinetrol® Xpur in Fat Mass Reduction on Overweight and Obese Subjects
October 31, 2019 updated by: Fytexia
This study aims to evaluate effects of a 16-week supplementation with a polyphenol rich extract, Sinetrol® Xpur, on fat mass accumulation and body weight management improvement.Subjects were overweight or obese and received polyphenol supplement or placebo.
A 4-week follow-up as performed to evaluate its effect after supplementation stop.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
77
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Murcia, Spain
- UCAM
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 51 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- overweight or obese (25 kg.m-2<BMI<42.5kg.m-2)
- healthy
Exclusion Criteria:
- metabolic or chronical disease with treatments (i.e.: diabetes, dyslipidemia, thyroiditis, inflammatory disease, immunological disease, infectious disease, asthma, anxiety and depression)
- food allergy to the ingredients of the product (grapefruit, orange, caffeine, guarana)
- involved in the prior 6 months in a chronic treatment program, eating disorders history, subjected to weight reduction by surgery
- start or quit smoking, high alcohol consumption
- pregnant, breastfeeding, wanting to have a baby,
- menopausal women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
|
|
Experimental: Verum
Sinetrol® Xpur
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in total body fat percentage loss versus bodyweight
Time Frame: week1; week16; week20
|
week1; week16; week20
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Pedro Alcaraz Ramon, UCAM
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2015
Primary Completion (Actual)
September 1, 2016
Study Completion (Actual)
September 1, 2017
Study Registration Dates
First Submitted
October 31, 2019
First Submitted That Met QC Criteria
October 31, 2019
First Posted (Actual)
November 4, 2019
Study Record Updates
Last Update Posted (Actual)
November 4, 2019
Last Update Submitted That Met QC Criteria
October 31, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SNTCT2015
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Change in Total Body Fat Mass Percentage Loss Versus Body Weight
-
Sulaimany Polytechnic universityCompletedImproving Body Composition | Novel Natural Gym Nutrient Formulation | Increase Muscle Mass | Reduce Body Fat Percentage | Enhancing Metabolic Health and Athletic PerformanceIraq
-
The University of Hong KongThe Hong Kong Jockey Club Charities TrustEnrolling by invitationOverweight or Obesity | Healthy Diet | Weight Change | Body Fat | Physical Activities | Muscle MassHong Kong
-
National Cheng-Kung University HospitalActive, not recruitingWeight Loss | Body Fat Rate Loss | Body Composition ChangeTaiwan
-
Amasya UniversityCompletedSedentary Lifestyle | Headache | Obesity & Overweight | Body Fat Percentage | Brain Grey Matter | Brain White MatterTurkey (Türkiye)
-
Yonsei UniversityCompletedWeight Loss | Visceral FatKorea, Republic of
-
Universitas SriwijayaCompletedBody Composition | Overweight and Obesity | Body Fat | Bone Mass | Lean Body Mass | Body WaterIndonesia
-
Columbia UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University...Completed
-
University of HelsinkiCompleted
-
University of LeedsDietary Assessment LtdCompletedWeight Loss | Colorectal Surgery | Weight Change, Body | Gastroenterology SurgeryUnited Kingdom
-
Leo WangBTS InternationalCompletedWeight | Body Fat Disorder | Bone MassChina
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States